Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Painful Diabetic Neuropathy Clear all
Completed Phase 2 Interventional

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01345045
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-639, pregabalin, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 6, 2026, 1:19 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain

NCT01620775
View directory record Official record
Conditions
Chronic Low Back Pain, Diabetic Peripheral Neuropathy, Knee Osteoarthritis
Interventions
MRIs, Pain testing
Other
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 2 Interventional

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

NCT06797869
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Interventions
CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
La Mesa, California • San Diego, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT04688671
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Interventions
ETX-018810, Placebo
Drug
Lead sponsor
Eliem Therapeutics (UK) Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 6, 2026, 1:19 AM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

NCT01770964
View directory record Official record
Conditions
Diabetes Mellitus, Painful Distal Symmetric Sensorimotor Polyneuropathy
Interventions
Pregabalin, placebo, Training Type A, Training Type B
Drug · Behavioral
Lead sponsor
Analgesic Solutions
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brighton, Massachusetts • Watertown, Massachusetts • Johnson City, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting Phase 2 Interventional

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

NCT04678895
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Withdrawn Not applicable Interventional

Exercise Induced Hypoalgesia Diabetes

NCT05296642
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain
Interventions
Moderate Cycling, Personalized Tourniquet System
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 6, 2026, 1:19 AM EDT
Not listed Phase 1Phase 2 Interventional

Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA

NCT05766969
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
CBD/PEA, Placebo
Drug
Lead sponsor
Pure Green Pharmaceuticals Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting Phase 2 Interventional

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322
View directory record Official record
Conditions
Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions
Pregabalin, Duloxetine, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

NCT07298408
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution
Drug
Lead sponsor
Florida A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

NCT05291975
View directory record Official record
Conditions
Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
Interventions
Erchonia® EVRL™, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • West Covina, California • Dunedin, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT03219320
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
NYX-2925, Placebo
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 6, 2026, 1:19 AM EDT
Withdrawn Not applicable Interventional

Oral Thiamine for the Treatment of Painful Diabetic Peripheral Neuropathy

NCT00279266
View directory record Official record
Conditions
Peripheral Neuropathy, Diabetes Mellitus, Diabetes Complications
Interventions
Thiamine
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 6, 2026, 1:19 AM EDT
Terminated Phase 3 Interventional Results available

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

NCT01288937
View directory record Official record
Conditions
Idiopathic Peripheral Neuropathy
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nociceptive Pain Fiber Response

NCT02696070
View directory record Official record
Conditions
Painful Peripheral Diabetic Neuropathy
Interventions
Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

NCT01939366
View directory record Official record
Conditions
Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
Interventions
Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

NCT02461225
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Erchonia® FX-635™, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation

NCT03769675
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
High Frequency Spinal Cord Stimulator
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 3 Interventional

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

NCT00135109
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

NCT00785577
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Placebo, Pregabalin, LY545694 21 mg, LY545694 49 mg, LY545694 105 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Greenbrae, California • Tustin, California • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 2 Interventional

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

NCT03664921
View directory record Official record
Conditions
Diabetic Neuropathies, Neuropathic Pain, Pain, Chronic
Interventions
Omnitram Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Anaheim, California • Cerritos, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 6, 2026, 1:19 AM EDT
Completed No phase listed Observational

Observational Study of the the Use of a Trigeminal Vagal Nerve Stimulator in the Routine Care of Native Americans With Diabetic Neuropathy Pain. Pain Scores, Drug Use and Glucose Measurements Will be Assessed

NCT07025356
View directory record Official record
Conditions
Diabetic Neuropathy With Neurologic Complication
Interventions
Implantation of a trigeminal Vagus cervical nerve stimulator system, Implantation of a neurostimulator system for trigeminal vagal cervical nerve stimulation
Drug · Device
Lead sponsor
Vagus Nerve Society
Other
Eligibility
18 Years to 89 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pine Ridge, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 6, 2026, 1:19 AM EDT